BioCentury
ARTICLE | Financial News

Acceleron, Stemline price upsized follow-ons

January 16, 2019 2:50 PM UTC

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch.

Acceleron said Wednesday that it raised $230 million through the sale of 5.3 million shares at $43. The price is a 7% discount to Acceleron's closing price of $46.44 on Monday, when it proposed after market hours to raise $200 million. Its shares slipped $2.52 to $43.92 on Tuesday, and lost another $1.11 to $42.81 on Wednesday. ...